220 related articles for article (PubMed ID: 35868851)
1. Identification of Small-Molecule Inhibitors of Fibroblast Growth Factor 23 Signaling via In Silico Hot Spot Prediction and Molecular Docking to α-Klotho.
Liu SH; Xiao Z; Mishra SK; Mitchell JC; Smith JC; Quarles LD; Petridis L
J Chem Inf Model; 2022 Aug; 62(15):3627-3637. PubMed ID: 35868851
[TBL] [Abstract][Full Text] [Related]
2. Novel Small Molecule Fibroblast Growth Factor 23 Inhibitors Increase Serum Phosphate and Improve Skeletal Abnormalities in
Xiao Z; Liu J; Liu SH; Petridis L; Cai C; Cao L; Wang G; Chin AL; Cleveland JW; Ikedionwu MO; Carrick JD; Smith JC; Quarles LD
Mol Pharmacol; 2021 Jun; 101(6):408-421. PubMed ID: 35339985
[TBL] [Abstract][Full Text] [Related]
3. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation.
Goetz R; Nakada Y; Hu MC; Kurosu H; Wang L; Nakatani T; Shi M; Eliseenkova AV; Razzaque MS; Moe OW; Kuro-o M; Mohammadi M
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):407-12. PubMed ID: 19966287
[TBL] [Abstract][Full Text] [Related]
4. FGF23 Neutralizing Antibody Ameliorates Hypophosphatemia and Impaired FGF Receptor Signaling in Kidneys of HMWFGF2 Transgenic Mice.
Du E; Xiao L; Hurley MM
J Cell Physiol; 2017 Mar; 232(3):610-616. PubMed ID: 27306296
[TBL] [Abstract][Full Text] [Related]
5. Targeted inhibition of Klotho binding to fibroblast growth factor 23 prevents hypophosphetemia.
Fakhar M; Rashid S
J Mol Graph Model; 2017 Aug; 75():9-19. PubMed ID: 28501532
[TBL] [Abstract][Full Text] [Related]
6. Phosphatonins: From Discovery to Therapeutics.
Kritmetapak K; Kumar R
Endocr Pract; 2023 Jan; 29(1):69-79. PubMed ID: 36210014
[TBL] [Abstract][Full Text] [Related]
7. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
Athonvarangkul D; Insogna KL
Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
[TBL] [Abstract][Full Text] [Related]
8. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
Fukumoto S
J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
[TBL] [Abstract][Full Text] [Related]
9. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
Kinoshita Y; Fukumoto S
Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
[TBL] [Abstract][Full Text] [Related]
10. Ectopic expression of Klotho in fibroblast growth factor 23 (FGF23)-producing tumors that cause tumor-induced rickets/osteomalacia (TIO).
Kinoshita Y; Takashi Y; Ito N; Ikegawa S; Mano H; Ushiku T; Fukayama M; Nangaku M; Fukumoto S
Bone Rep; 2019 Jun; 10():100192. PubMed ID: 30627598
[TBL] [Abstract][Full Text] [Related]
11. FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism.
Fukumoto S
Calcif Tissue Int; 2016 Apr; 98(4):334-40. PubMed ID: 26126937
[TBL] [Abstract][Full Text] [Related]
12. Soluble Klotho causes hypomineralization in Klotho-deficient mice.
Minamizaki T; Konishi Y; Sakurai K; Yoshioka H; Aubin JE; Kozai K; Yoshiko Y
J Endocrinol; 2018 Jun; 237(3):285-300. PubMed ID: 29632215
[TBL] [Abstract][Full Text] [Related]
13. Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease.
Yanucil C; Kentrup D; Campos I; Czaya B; Heitman K; Westbrook D; Osis G; Grabner A; Wende AR; Vallejo J; Wacker MJ; Navarro-Garcia JA; Ruiz-Hurtado G; Zhang F; Song Y; Linhardt RJ; White K; Kapiloff MS; Faul C
Kidney Int; 2022 Aug; 102(2):261-279. PubMed ID: 35513125
[TBL] [Abstract][Full Text] [Related]
14. Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders.
Ramos P; Larson B; Ashrafzadeh-Kian S; Ito N; Kato H; Bornhorst JA; Algeciras-Schimnich A
Endocr Pract; 2023 Mar; 29(3):193-198. PubMed ID: 36627024
[TBL] [Abstract][Full Text] [Related]
15. A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia.
Xiao Z; Riccardi D; Velazquez HA; Chin AL; Yates CR; Carrick JD; Smith JC; Baudry J; Quarles LD
Sci Signal; 2016 Nov; 9(455):ra113. PubMed ID: 27879395
[TBL] [Abstract][Full Text] [Related]
16. Development of A Cell-Based Assay to Identify Small Molecule Inhibitors of FGF23 Signaling.
Diener S; Schorpp K; Strom TM; Hadian K; Lorenz-Depiereux B
Assay Drug Dev Technol; 2015 Oct; 13(8):476-87. PubMed ID: 26461432
[TBL] [Abstract][Full Text] [Related]
17. Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO.
Xiao L; Naganawa T; Lorenzo J; Carpenter TO; Coffin JD; Hurley MM
J Biol Chem; 2010 Jan; 285(4):2834-46. PubMed ID: 19933269
[TBL] [Abstract][Full Text] [Related]
18. FGF23: mediator of poor prognosis in a sizeable subgroup of patients with castration-resistant prostate cancer presenting with severe hypophosphatemia?
Lee EK; Martinez MC; Blakely K; Santos KD; Hoang VC; Chow A; Emmenegger U
Med Hypotheses; 2014 Oct; 83(4):482-7. PubMed ID: 25155552
[TBL] [Abstract][Full Text] [Related]
19. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status.
Carpenter TO; Insogna KL; Zhang JH; Ellis B; Nieman S; Simpson C; Olear E; Gundberg CM
J Clin Endocrinol Metab; 2010 Nov; 95(11):E352-7. PubMed ID: 20685863
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model.
Nakatani T; Ohnishi M; Razzaque MS
FASEB J; 2009 Nov; 23(11):3702-11. PubMed ID: 19584304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
